 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IO Biotech (NASDAQ:IOBT  Get Free Report)s stock had its buy rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga...

IO Biotech (NASDAQ:IOBT) Stock Rating Reaffirmed by HC Wainwright

Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancer NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE...

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology...

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech, Inc. (NASDAQ:IOBT  Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 546,900 shares, a growth of 29.9% from the July 31st total of 421,000 shares. Based on an average daily ...

IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 29.9% in August

IO Biotech, Inc. (NASDAQ:IOBT  Get Free Report) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 421,000 shares...

Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Decreases By 5.9%

IO Biotech (NASDAQ:IOBT Free Report) had its price objective trimmed by Morgan Stanley from $11.00 to $7.00 in a report published on Tuesday, Benzinga reports. The firm currently has an overweight rating on the stock. Separately, HC Wainwright restated a buy rating and issued a $8.00 price target (...

IO Biotech (NASDAQ:IOBT) Given New $7.00 Price Target at Morgan Stanley

Related Stocks: IOBT, ADMA, GLPG, QDEL, EOLS, AMLX...

Stonepine Capital Management, LLC Acquires New Stake in IO Biotech Inc

HC Wainwright reaffirmed their buy rating on shares of IO Biotech (NASDAQ:IOBT  Free Report) in a research note published on Friday, Benzinga reports. They currently have a $8.00 price target...

HC Wainwright Reaffirms Buy Rating for IO Biotech (NASDAQ:IOBT)

Achieved significant enrollment milestone in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in advanced melanoma; full enrollment anticipated by the end of 2023Initiated enrollment in three investigator-initiated trials which the company is supporting to evaluate IO102-IO103 in combination ...

IO Biotech Announces 2023 Second Quarter Results

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, announced the appointment of Heidi Hunter to its board of directors. Ms. Hunter, an ...

IO Biotech Appoints Heidi Hunter to its Board of Directors

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Watchers	334
52-Wk Low	$1.20
52-Wk High	$3.52

Market Cap	$38.32M
Volume (M)	8,890.00
52-Wk High	$3.52
52-Wk Low	$1.20

IOBT IO Biotech Inc

About

Feed

News

Earnings

Fundamentals